FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955938239> ?p ?o ?g. }

• W2955938239 endingPage "CT086" @default.
• W2955938239 startingPage "CT086" @default.
• W2955938239 abstract "Abstract Background: Blockade of the PD/PD-L1 pathway is an effective immunotherapy for NSCLC, however rational combination therapies are needed to overcome resistance mechanisms. VX15/2503 (pepinemab) is an IgG4 humanized monoclonal antibody targeting semaphorin 4D (SEMA4D, CD100). In vivo preclinical models demonstrated antibody blockade of SEMA4D promoted immune infiltration and reduced function and recruitment of immunosuppressive myeloid cells within the tumor. Importantly, preclinical combinations of anti-SEMA4D with various immunotherapies enhanced T cell activity and tumor regression. Avelumab is a fully human IgG1 antibody specific for PD-L1 and has been approved for both Merkel cell and urothelial carcinomas. The CLASSICAL-Lung clinical trial tests the combination of pepinemab with avelumab to couple immune activation via checkpoint inhibition with beneficial modifications of the immune microenvironment via pepinemab. Here, we present interim results of the dose escalation portion of the CLASSICAL-Lung study. Methods: This Phase Ib/II, open label, single arm, first-in-human combination study is designed to evaluate the safety, tolerability and efficacy of pepinemab in combination with avelumab in 62 subjects with advanced (IIIB/IV) NSCLC. The trial is split into dose escalation (n=12) and dose expansion (n=50) phases. The dose escalation portion includes patients who are immunotherapy naïve and have either progressed or declined standard first or second-line systemic anticancer therapy. The expansion phase includes a similar patient cohort as well as a second cohort of patients whose tumors progressed during or following immunotherapy. Patients in the dose escalation cohorts received ascending doses of pepinemab (5, 10, 20 mg/kg, Q2W) in combination with avelumab (10mg/kg, Q2W). The primary objective of dose escalation is safety, tolerability, and identification of the RP2D for dose expansion. Secondary objectives include evaluation of efficacy, immunogenicity, and PK/PD, and an exploratory objective is to identify candidate biomarkers of activity. Results / Conclusions: Dose escalation was successfully completed. The combination was found to be well tolerated at all dose levels tested and the RP2D was selected as 10mg/kg pepinemab Q2W (with 10mg/kg avelumab Q2W) for the dose expansion phase. No concerning safety signals have been identified to date. The most frequent related AEs were grades 1 or 2 fatigue, pyrexia, or chills; no grade 3 AE occurred in more than one subject. One DLT, a grade 3 pulmonary embolism occurred in the 10mg/kg pepinemab cohort, resolved and did not recur in that same subject or additional subjects in any cohort. The disease control rate to date in all dose escalation patients treated for at least two months is 90%. More detailed data from the dose escalation cohorts will be presented, as well as an enrollment update for the dose expansion phase. Clinical trial information: NCT03268057 Citation Format: Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest Smith, Maurice Zauderer, Andreas Schröeder, Kevin Chin, Thaddeus Beck, Megan Baumgart, Rachel E. Sanborn, Jonathan W. Goldman. Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT086." @default.
• W2955938239 created "2019-07-12" @default.
• W2955938239 creator A5001292309 @default.
• W2955938239 creator A5001835930 @default.
• W2955938239 creator A5005462156 @default.
• W2955938239 creator A5017065543 @default.
• W2955938239 creator A5019666128 @default.
• W2955938239 creator A5022624265 @default.
• W2955938239 creator A5030373204 @default.
• W2955938239 creator A5036134937 @default.
• W2955938239 creator A5036970226 @default.
• W2955938239 creator A5038777347 @default.
• W2955938239 creator A5050974773 @default.
• W2955938239 creator A5065056301 @default.
• W2955938239 creator A5082243246 @default.
• W2955938239 creator A5089699061 @default.
• W2955938239 date "2019-07-01" @default.
• W2955938239 modified "2023-09-27" @default.
• W2955938239 title "Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC" @default.
• W2955938239 doi "https://doi.org/10.1158/1538-7445.am2019-ct086" @default.
• W2955938239 hasPublicationYear "2019" @default.
• W2955938239 type Work @default.
• W2955938239 sameAs 2955938239 @default.
• W2955938239 citedByCount "0" @default.
• W2955938239 crossrefType "journal-article" @default.
• W2955938239 hasAuthorship W2955938239A5001292309 @default.
• W2955938239 hasAuthorship W2955938239A5001835930 @default.
• W2955938239 hasAuthorship W2955938239A5005462156 @default.
• W2955938239 hasAuthorship W2955938239A5017065543 @default.
• W2955938239 hasAuthorship W2955938239A5019666128 @default.
• W2955938239 hasAuthorship W2955938239A5022624265 @default.
• W2955938239 hasAuthorship W2955938239A5030373204 @default.
• W2955938239 hasAuthorship W2955938239A5036134937 @default.
• W2955938239 hasAuthorship W2955938239A5036970226 @default.
• W2955938239 hasAuthorship W2955938239A5038777347 @default.
• W2955938239 hasAuthorship W2955938239A5050974773 @default.
• W2955938239 hasAuthorship W2955938239A5065056301 @default.
• W2955938239 hasAuthorship W2955938239A5082243246 @default.
• W2955938239 hasAuthorship W2955938239A5089699061 @default.
• W2955938239 hasConcept C126322002 @default.
• W2955938239 hasConcept C143998085 @default.
• W2955938239 hasConcept C159654299 @default.
• W2955938239 hasConcept C197934379 @default.
• W2955938239 hasConcept C203014093 @default.
• W2955938239 hasConcept C2777381376 @default.
• W2955938239 hasConcept C2777701055 @default.
• W2955938239 hasConcept C2778375690 @default.
• W2955938239 hasConcept C2779015954 @default.
• W2955938239 hasConcept C2780030458 @default.
• W2955938239 hasConcept C542903549 @default.
• W2955938239 hasConcept C71924100 @default.
• W2955938239 hasConcept C8891405 @default.
• W2955938239 hasConceptScore W2955938239C126322002 @default.
• W2955938239 hasConceptScore W2955938239C143998085 @default.
• W2955938239 hasConceptScore W2955938239C159654299 @default.
• W2955938239 hasConceptScore W2955938239C197934379 @default.
• W2955938239 hasConceptScore W2955938239C203014093 @default.
• W2955938239 hasConceptScore W2955938239C2777381376 @default.
• W2955938239 hasConceptScore W2955938239C2777701055 @default.
• W2955938239 hasConceptScore W2955938239C2778375690 @default.
• W2955938239 hasConceptScore W2955938239C2779015954 @default.
• W2955938239 hasConceptScore W2955938239C2780030458 @default.
• W2955938239 hasConceptScore W2955938239C542903549 @default.
• W2955938239 hasConceptScore W2955938239C71924100 @default.
• W2955938239 hasConceptScore W2955938239C8891405 @default.
• W2955938239 hasIssue "13_Supplement" @default.
• W2955938239 hasLocation W29559382391 @default.
• W2955938239 hasOpenAccess W2955938239 @default.
• W2955938239 hasPrimaryLocation W29559382391 @default.
• W2955938239 hasRelatedWork W1969657123 @default.
• W2955938239 hasRelatedWork W1996150995 @default.
• W2955938239 hasRelatedWork W1999686187 @default.
• W2955938239 hasRelatedWork W2483666426 @default.
• W2955938239 hasRelatedWork W2774483623 @default.
• W2955938239 hasRelatedWork W2984962695 @default.
• W2955938239 hasRelatedWork W3114278456 @default.
• W2955938239 hasRelatedWork W3139770254 @default.
• W2955938239 hasRelatedWork W4361947372 @default.
• W2955938239 hasRelatedWork W2192829665 @default.
• W2955938239 hasVolume "79" @default.
• W2955938239 isParatext "false" @default.
• W2955938239 isRetracted "false" @default.
• W2955938239 magId "2955938239" @default.
• W2955938239 workType "article" @default.